Gulf International Bank UK Ltd boosted its position in shares of Becton Dickinson and Co. (NYSE:BDX) by 0.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 65,407 shares of the company’s stock after buying an additional 400 shares during the period. Gulf International Bank UK Ltd’s holdings in Becton Dickinson and were worth $11,755,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Point72 Asia Hong Kong Ltd purchased a new stake in shares of Becton Dickinson and during the second quarter worth approximately $119,000. Acrospire Investment Management LLC increased its stake in shares of Becton Dickinson and by 458.0% in the second quarter. Acrospire Investment Management LLC now owns 731 shares of the company’s stock worth $124,000 after buying an additional 600 shares during the last quarter. Iowa State Bank purchased a new stake in shares of Becton Dickinson and during the second quarter worth approximately $137,000. First Personal Financial Services increased its stake in shares of Becton Dickinson and by 101.7% in the second quarter. First Personal Financial Services now owns 827 shares of the company’s stock worth $140,000 after buying an additional 417 shares during the last quarter. Finally, First PREMIER Bank increased its stake in shares of Becton Dickinson and by 251.0% in the third quarter. First PREMIER Bank now owns 839 shares of the company’s stock worth $151,000 after buying an additional 600 shares during the last quarter. Hedge funds and other institutional investors own 81.35% of the company’s stock.

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Becton Dickinson and Co. (NYSE:BDX) traded down 1.99% during mid-day trading on Wednesday, reaching $169.30. 586,259 shares of the company’s stock traded hands. The company has a market capitalization of $35.95 billion, a price-to-earnings ratio of 37.71 and a beta of 1.04. Becton Dickinson and Co. has a 52-week low of $129.50 and a 52-week high of $181.76. The company has a 50-day moving average of $171.40 and a 200-day moving average of $172.45.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Thursday, November 3rd. The company reported $2.12 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.09 by $0.03. Becton Dickinson and had a net margin of 7.82% and a return on equity of 24.45%. The firm had revenue of $3.23 billion for the quarter, compared to the consensus estimate of $3.22 billion. During the same period in the previous year, the company earned $1.94 earnings per share. The company’s quarterly revenue was up 5.6% on a year-over-year basis. Equities research analysts expect that Becton Dickinson and Co. will post $9.52 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 30th. Shareholders of record on Friday, December 9th will be issued a $0.73 dividend. This is an increase from Becton Dickinson and’s previous quarterly dividend of $0.66. This represents a $2.92 annualized dividend and a dividend yield of 1.69%. The ex-dividend date is Wednesday, December 7th. Becton Dickinson and’s payout ratio is currently 58.54%.

COPYRIGHT VIOLATION NOTICE: “Becton Dickinson and Co. (BDX) Position Raised by Gulf International Bank UK Ltd” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2016/11/30/becton-dickinson-and-co-bdx-position-raised-by-gulf-international-bank-uk-ltd.html.

BDX has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $189.00 price objective for the company in a research report on Friday, November 25th. Deutsche Bank AG restated a “buy” rating and issued a $189.00 price objective (down previously from $197.00) on shares of Becton Dickinson and in a research report on Friday, November 4th. Argus restated a “buy” rating and issued a $185.00 price objective on shares of Becton Dickinson and in a research report on Friday, October 21st. Jefferies Group reiterated a “buy” rating on shares of Becton Dickinson and in a research report on Friday, August 5th. Finally, Leerink Swann reiterated a “hold” rating on shares of Becton Dickinson and in a research report on Tuesday, August 9th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. Becton Dickinson and presently has a consensus rating of “Buy” and a consensus price target of $175.65.

In other news, insider Linda M. Tharby sold 11,704 shares of the business’s stock in a transaction dated Tuesday, September 6th. The shares were sold at an average price of $177.27, for a total value of $2,074,768.08. Following the completion of the sale, the insider now owns 22,146 shares of the company’s stock, valued at $3,925,821.42. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Stephen Sichak sold 10,352 shares of the business’s stock in a transaction dated Friday, November 4th. The shares were sold at an average price of $176.10, for a total transaction of $1,822,987.20. Following the completion of the sale, the insider now directly owns 26,892 shares of the company’s stock, valued at approximately $4,735,681.20. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

5 Day Chart for NYSE:BDX

Receive News & Stock Ratings for Becton Dickinson and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Co. and related stocks with our FREE daily email newsletter.